IRIDEX CORPIRIXEarnings & Financial Report
IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.
IRIX Q4 FY2025 Key Financial Metrics
Revenue
$14.7M
Gross Profit
$5.5M
Operating Profit
N/A
Net Profit
N/A
Gross Margin
37.2%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-69.7%
IRIDEX CORP Q4 FY2025 Financial Summary
IRIDEX CORP reported revenue of $14.7M (down 69.7% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $9.2M.
Key Financial Metrics
| Total Revenue | $14.7M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 37.2% |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
IRIDEX CORP Annual Revenue by Year
IRIDEX CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $52.7M).
IRIDEX CORP Quarterly Revenue & Net Profit History
IRIDEX CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $14.7M | -69.7% | N/A | N/A |
| Q3 FY2025 | $12.5M | +7.8% | $-1.6M | -12.6% |
| Q2 FY2025 | $13.6M | +7.4% | $-994.0K | -7.3% |
| Q1 FY2025 | $11.9M | +1.1% | $-1.7M | -14.2% |
| Q4 FY2024 | $12.7M | +1.9% | $-834.0K | -6.6% |
| Q3 FY2024 | $11.6M | -9.9% | $-1.9M | -16.7% |
| Q2 FY2024 | $12.6M | -1.7% | $-2.7M | -21.2% |
| Q1 FY2024 | $11.8M | -14.2% | $-3.5M | -29.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.8M | $12.6M | $11.6M | $12.7M | $11.9M | $13.6M | $12.5M | $14.7M |
| YoY Growth | -14.2% | -1.7% | -9.9% | 1.9% | 1.1% | 7.4% | 7.8% | -69.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $34.1M | $31.2M | $30.2M | $29.1M | $34.2M | $31.6M | $28.4M | $29.2M |
| Liabilities | $27.6M | $27.0M | $27.5M | $27.0M | $27.4M | $25.5M | $23.7M | $24.2M |
| Equity | $6.5M | $4.2M | $2.6M | $2.1M | $852000 | $6.1M | $4.7M | N/A |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-1.3M | $-3.1M | $-1.2M | $-1.1M | $-397000 | $-1.2M |